Annals of Internal Medicine

Adial Pharmaceuticals Reports First Quarter 2024 Financial Results and Provides Business Update

Retrieved on: 
星期三, 五月 15, 2024
Partnership, Patient, OUD, Patent, European Journal, Annals of Internal Medicine, Exercise, FDA, Opioid use disorder, Drug development, Chemistry, ALD, Liver transplantation, GLEN, Open access, Manuscript, Data analysis, Internal medicine, Research, G&A, Pharmaceutical industry

GLEN ALLEN, Va., May 15, 2024 (GLOBE NEWSWIRE) -- Adial Pharmaceuticals, Inc. (NASDAQ: ADIL) (“Adial” or the “Company”), a clinical-stage biopharmaceutical company focused on developing therapies for the treatment and prevention of addiction and related disorders, today provided a business update and reported its financial results for the first quarter of 2024.

Key Points: 
  • GLEN ALLEN, Va., May 15, 2024 (GLOBE NEWSWIRE) -- Adial Pharmaceuticals, Inc. (NASDAQ: ADIL) (“Adial” or the “Company”), a clinical-stage biopharmaceutical company focused on developing therapies for the treatment and prevention of addiction and related disorders, today provided a business update and reported its financial results for the first quarter of 2024.
  • Cary Claiborne, President and Chief Executive Officer of Adial, stated, “We are making steady progress as it relates to AD04.
  • To support our efforts, we formally hired Tony Goodman as our Chief Operating Officer during the quarter.
  • Cash and cash equivalents were $5.0 million as of March 31, 2024, compared to $2.8 million as of December 31, 2023.

The International Myeloma Foundation and Black Swan Research Initiative® Announce the Release of New iStopMM Cohort Study: A Multivariable Prediction Model for Bone Marrow Sampling on Individuals with MGUS

Retrieved on: 
星期四, 四月 11, 2024
Immunoglobulin G, International Myeloma Foundation, University, Bone marrow, Mayo Clinic, Randomized controlled trial, Overfitting, Multiple myeloma, Annals of Internal Medicine, MGUS, Probability, Risk, Monoclonal gammopathy, Immunoglobulin M, Research, Calibration, Immunoglobulin A, IQR, European Research Council, Clinical, IMF, SMM, B cell, Black swan, Diagnosis, Clutch (eggs), Internal medicine, Smouldering, Lymphoproliferative disorders, BSRI, Ageing, Medical device

IMF Chief Scientific Officer and co-author of the iStopMM cohort study Dr. Brian G.M.

Key Points: 
  • IMF Chief Scientific Officer and co-author of the iStopMM cohort study Dr. Brian G.M.
  • Groups 2 and 3 were evaluated at the study clinic for initial assessment and follow-up, including bone marrow sampling,” according to the study.
  • However, [this] model requires validation in other populations.”
    To know the full details of the iStopMM cohort study , view it online.
  • This research was funded by the International Myeloma Foundation and the European Research Council.

Adial Pharmaceuticals Announces Peer-Reviewed Publication Highlighting Promising Safety Data and High Patient Compliance in a Clinical Trial of AD04 as a Potential Treatment for Alcohol Use Disorder

Retrieved on: 
星期三, 四月 10, 2024
Liver injury, Safety, GLEN, Epistasis, ALT, Patient, European Journal, Liver, ALD, GGT, Annals of Internal Medicine, Aes, Manuscript, Internal medicine, Liver transplantation, Open access

According to the publication, low-dose AD04 did not significantly change biochemical markers of liver injury, such as ALT, AST, and Serum Bilirubin.

Key Points: 
  • According to the publication, low-dose AD04 did not significantly change biochemical markers of liver injury, such as ALT, AST, and Serum Bilirubin.
  • Additionally, while patients with AUD displayed elevated GGT levels, typically associated with increased alcohol consumption, this parameter remained unaffected by low-dose AD04.
  • This peer-reviewed publication emphasizes the safety and potential of AD04 in addressing the critical needs of individuals suffering from AUD and ALD.
  • Most importantly, the publication highlighted the potential of AD04 for the treatment for AUD among patients with a specified genetic background.

American College of Physicians issues clinical recommendations for newer pharmacological treatments of adults with Type 2 diabetes

Retrieved on: 
星期五, 四月 19, 2024
ACP, Mortality, MACP, Stroke, Annals of Internal Medicine, American College, Meta-analysis, Risk, DPP-4, Guideline, Development, Assessment, Type 2 diabetes, Type 2, GRADE, Patient, Diabetes, Myocardial infarction, Weight loss, Internal medicine, Hospital, Chronic kidney disease, Metformin, Hypoglycemia, Heart, Systematic review, Disease

BOSTON, April 19, 2024 /PRNewswire/ -- The American College of Physicians (ACP) today released an update of its 2017 guideline with clinical recommendations for the use of newer pharmacological treatments of adults with Type 2 diabetes. The clinical guideline is based on the best available evidence for effectiveness, comparative benefits and harms, consideration of patients' values and preferences, and costs. Newer Pharmacological Treatments in Adults with Type 2 Diabetes: A Clinical Guideline from the American College of Physicians was published today in Annals of Internal Medicine.

Key Points: 
  • Reviews evidence of newer medications, recommends adding to metformin
    BOSTON, April 19, 2024 /PRNewswire/ -- The American College of Physicians (ACP) today released an update of its 2017 guideline with clinical recommendations for the use of newer pharmacological treatments of adults with Type 2 diabetes.
  • Newer Pharmacological Treatments in Adults with Type 2 Diabetes: A Clinical Guideline from the American College of Physicians was published today in Annals of Internal Medicine.
  • ACP today released clinical recommendations for the use of newer treatments in adults with Type 2 diabetes.
  • This clinical guideline is based on a systematic review of the effectiveness and harms of newer pharmacological treatments for Type 2 diabetes.

Together by Renee, the all-in-one AI health assistant, improves care for aging Americans with the new Together Companion personal chatbot

Retrieved on: 
星期三, 三月 20, 2024
Software, Men, General Health, Telemedicine, Virtual Medicine, Consumer, Mental Health, Apps, Applications, Technology, Artificial Intelligence, Health Technology, Women, Seniors, Health, Internal medicine, Diabetes, Patient, National Council, Mental health, History, Arthritis, Nausea, Pharmacy, Annals of Internal Medicine, Multimedia, Ageing, Medical device

The Together Companion helps users stay on track toward following their care plans and achieving better health.

Key Points: 
  • The Together Companion helps users stay on track toward following their care plans and achieving better health.
  • 10 in the wellness and personal care category on Fast Company’s 2024 Most Innovative Companies list.
  • For medical appointments, the Together Companion allows users to upload written care plans and record actual in-appointment verbal instructions.
  • The Together Companion provides accurate, timely, contextual and highly personalized answers, and can even proactively follow up with patients regarding their care.

Alimentiv Inc. Announces New Scientific Advisors Leading Research In GI-Related Therapeutics

Retrieved on: 
星期五, 十月 13, 2023
Mount Sinai, Icahn School of Medicine at Mount Sinai, Contract research organization, Internal medicine, MS, Abstract, Research, VARSITY, The New England Journal of Medicine, Crohn's and Colitis Canada, Therapy, IBD, Safety, University, Inflammatory bowel disease, Annals of Internal Medicine, JAMA, Inflammatory Bowel Diseases, Publication, United States Army Medical Research and Development Command, Dean, Patient, Pharmaceutical industry, MD, Nature, Medicine, Lancet

LONDON, ON, Oct. 13, 2023 /PRNewswire/ - Alimentiv Inc. ("Alimentiv"), a leading Contract Research Organization focused on GI-related therapeutics, is pleased to announce the addition of new scientific advisors to its scientific advisory board.

Key Points: 
  • LONDON, ON, Oct. 13, 2023 /PRNewswire/ - Alimentiv Inc. ("Alimentiv"), a leading Contract Research Organization focused on GI-related therapeutics, is pleased to announce the addition of new scientific advisors to its scientific advisory board.
  • The advisors are internationally recognized experts in designing and conducting clinical research in Inflammatory Bowel Disease.
  • Their contributions to the field have been essential in progressing the development of novel therapies in IBD and improving patient outcomes.
  • He holds the Crohn's Colitis Canada Endowed Research Chair in Inflammatory Bowel Disease and is an executive member of the IOIBD.

Alimentiv Inc. Announces New Scientific Advisors Leading Research In GI-Related Therapeutics

Retrieved on: 
星期五, 十月 13, 2023
Mount Sinai, Icahn School of Medicine at Mount Sinai, Contract research organization, Internal medicine, MS, Abstract, Research, VARSITY, The New England Journal of Medicine, Crohn's and Colitis Canada, Therapy, IBD, Safety, University, Inflammatory bowel disease, Annals of Internal Medicine, JAMA, Inflammatory Bowel Diseases, Publication, United States Army Medical Research and Development Command, Dean, Patient, Pharmaceutical industry, MD, Nature, Medicine, Lancet

LONDON, ON, Oct. 13, 2023 /PRNewswire/ -- Alimentiv Inc. ("Alimentiv"), a leading Contract Research Organization focused on GI-related therapeutics, is pleased to announce the addition of new scientific advisors to its scientific advisory board.

Key Points: 
  • LONDON, ON, Oct. 13, 2023 /PRNewswire/ -- Alimentiv Inc. ("Alimentiv"), a leading Contract Research Organization focused on GI-related therapeutics, is pleased to announce the addition of new scientific advisors to its scientific advisory board.
  • The advisors are internationally recognized experts in designing and conducting clinical research in Inflammatory Bowel Disease.
  • Their contributions to the field have been essential in progressing the development of novel therapies in IBD and improving patient outcomes.
  • He holds the Crohn's Colitis Canada Endowed Research Chair in Inflammatory Bowel Disease and is an executive member of the IOIBD.

What Is the Impact of Predictive AI in the Health Care Setting? Findings underscore the need to track individuals affected by machine learning predictions.

Retrieved on: 
星期一, 十月 9, 2023
Nursing care plan, Mount Sinai Health System, Icahn School of Medicine at Mount Sinai, Internal medicine, Doctor of Philosophy, Beth Israel Deaconess Medical Center, Machine learning, Death, D3M, Sepsis, Urology, MPH, Roger Hawkins (drummer), Mortality, University, Annals of Internal Medicine, Artificial intelligence, Department of Medicine – University of Pamplona, Kidney, Use, Data-driven, Associate, Learning, Patient, Management, Nursing, MD, RN, Medicine

NEW YORK, Oct. 9, 2023 /PRNewswire-PRWeb/ -- Models built on machine learning in health care can be victims of their own success, according to researchers at the Icahn School of Medicine and the University of Michigan.

Key Points: 
  • Their study assessed the impact of implementing predictive models on the subsequent performance of those and other models.
  • Their study assessed the impact of implementing predictive models on the subsequent performance of those and other models.
  • "These findings are equally applicable outside of health care settings and extend to predictive models in general.
  • The paper is titled "Implications of the Use of Artificial Intelligence Predictive Models in Health Care Settings: A Simulation Study."

Sanguina Raises $2.8M in Series A Funding to Drive Innovation in Home-Based Testing and Wellness Management

Retrieved on: 
星期二, 七月 25, 2023
Health Technology, Technology, Apps, Applications, Other Consumer, General Health, Women, Medical Devices, Men, Artificial Intelligence, Baby, Maternity, Clinical Trials, Family, Biotechnology, Consumer, Health, Mobile, Wireless, Emory University, Dehydration, JAMA, Woman, Georgia Institute of Technology College of Design, Multimedia, Biomarker, Annals of Internal Medicine, Doctor of Philosophy, Aspirin, CDC, Child, American Medical Association, History of the Georgia Institute of Technology, Journal, MD, Anemia, Korea Disease Control and Prevention Agency, Internal medicine, Invention, Artificial intelligence, Conditional sentence, FDA, Nursing, Medical device

Sanguina, a leading biotech company focused on providing rapid home-based testing and management solutions, announced today the successful completion of its $2.8m Series A funding round.

Key Points: 
  • Sanguina, a leading biotech company focused on providing rapid home-based testing and management solutions, announced today the successful completion of its $2.8m Series A funding round.
  • The funding will be used to accelerate the development and expansion of Sanguina's innovative blood health management digital and at-home-based platforms.
  • With advancements in home testing and artificial intelligence, the management of anemia and other chronic conditions is moving towards preventive and personalized medicine.
  • With the successful launch of anemia management through the AnemoCheck app and point-of-care test, Sanguina has taken a major stride towards revolutionizing home-based testing and personalized disease management.

BetterLife Highlights American College of Physicians’ Updated Guidelines for Treating Depression and Announces Closing of Private Placement

Retrieved on: 
星期四, 七月 13, 2023
Unit, CSE, Lysergic acid diethylamide, Physician, Membrane protein, DSM-IV codes, Annals of Internal Medicine, American College of Physicians, MDD, Patient, Offering, Internal medicine, Neuro, American College, ACP, Major depressive disorder, Pharmaceutical industry

We believe that our compound, BETR-001, has the potential to overcome the hurdles faced by psychedelics, making it potentially a treatment for a broader and more inclusive range of patients.

Key Points: 
  • We believe that our compound, BETR-001, has the potential to overcome the hurdles faced by psychedelics, making it potentially a treatment for a broader and more inclusive range of patients.
  • BETR-001 is a non-hallucinogenic derivative of lysergic acid diethylamide (“LSD”) and covered by BetterLife’s pending patents.
  • Based on its neuro-receptor activity profile in preclinical studies, we believe that BetterLife’s BETR-001 has significant therapeutic potential in various neuro-psychiatric disorders.
  • The Units sold pursuant to the Offering will be subject to a four month hold period pursuant to applicable Canadian securities laws.